Nov 9 (Reuters) - Shares of Mallinckrodt Plc fell as much as 26 percent on Monday after short-seller Citron Research called the drugmaker “a far worse offender of the reimbursement system” in a tweet.
Citron also indicated that it would disclose more in a report. (bit.ly/1ScY0O9)
Shares of Mallinckrodt - which makes specialty drugs, medical imaging agents and generic drugs - were down 15 percent at $59.01 on the New York Stock Exchange. (Reporting by Vidya L Nathan in Bengaluru; Editing by Anil D‘Silva)